FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Immunome Inc Soars After Antibody Cocktail Neutralizes Delta variant in Pre-Clinical Testing”
Immunome Inc. (NASDAQ: IMNM) surged over 43% in premarket trading after the company announced that its three-antibody cocktail has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant.
The cocktail, IMM-BCP-01, showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance and the Company plans to submit an IND application with the U.S. Food and Drug Administration during this quarter.
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19.
For more information, please visit: Immunome Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.